Frontrunners in RSV vaccine race will face scrutiny from U.S. officials this week February 28, 2023 The frontrunners in a crowded race to develop the first vaccine for respiratory syncytial virus (RSV) — pharmaceutical giants Pfizer and GSK — will face scrutiny from a panel of U.S. experts this week. Labels: CBC | Health News health Share to: Twitter Facebook URL Print Email
Post a Comment
EmoticonClick to see the code!
To insert emoticon you must added at least one space before the code.